Quantitative Evaluation of Disease Progression in a Longitudinal Mild Cognitive Impairment Cohort

Hilkka Runtti (Corresponding Author), Jussi Mattila, Mark van Gils, Juha Koikkalainen, Hilkka Soininen, Jyrki Lötjönen

Research output: Contribution to journalArticleScientificpeer-review

15 Citations (Scopus)

Abstract

Several neuropsychological tests and biomarkers of Alzheimer's disease (AD) have been validated and their evolution over time has been explored. In this study, multiple heterogeneous predictors of AD were combined using a supervised learning method called Disease State Index (DSI). The behavior of DSI values over time was examined to study disease progression quantitatively in a mild cognitive impairment (MCI) cohort. The DSI method was applied to longitudinal data from 140 MCI cases that progressed to AD and 149 MCI cases that did not progress to AD during the follow-up. The data included neuropsychological tests, brain volumes from magnetic resonance imaging, cerebrospinal fluid samples, and apolipoprotein E from the Alzheimer's Disease Neuroimaging Initiative database. Linear regression of the longitudinal DSI values (including the DSI value at the point of MCI to AD conversion) was performed for each subject having at least three DSI values available (147 non-converters, 126 converters). Converters had five times higher slopes and almost three times higher intercepts than non-converters. Two subgroups were found in the group of non-converters: one group with stable DSI values over time and another group with clearly increasing DSI values suggesting possible progression to AD in the future. The regression parameters differentiated between the converters and the non-converters with classification accuracy of 76.9% for the slopes and 74.6% for the intercepts. In conclusion, this study demonstrated that quantifying longitudinal patient data using the DSI method provides valid information for follow-up of disease progression and support for decision making.
Original languageEnglish
Pages (from-to)49-61
Number of pages13
JournalJournal of Alzheimer's Disease
Volume39
Issue number1
DOIs
Publication statusPublished - 2014
MoE publication typeA1 Journal article-refereed

Fingerprint

Disease Progression
Alzheimer Disease
Neuropsychological Tests
Cognitive Dysfunction
Apolipoproteins E
Neuroimaging
Cerebrospinal Fluid
Linear Models
Decision Making
Biomarkers
Magnetic Resonance Imaging
Learning
Databases
Brain

Keywords

  • Alzheimer's disease
  • biomarkers
  • data mining
  • decision support techniques
  • early diagnosis
  • mild cognitive impairment

Cite this

Runtti, Hilkka ; Mattila, Jussi ; van Gils, Mark ; Koikkalainen, Juha ; Soininen, Hilkka ; Lötjönen, Jyrki. / Quantitative Evaluation of Disease Progression in a Longitudinal Mild Cognitive Impairment Cohort. In: Journal of Alzheimer's Disease. 2014 ; Vol. 39, No. 1. pp. 49-61.
@article{9d07ac344f8c4d9180f05b8055091cd6,
title = "Quantitative Evaluation of Disease Progression in a Longitudinal Mild Cognitive Impairment Cohort",
abstract = "Several neuropsychological tests and biomarkers of Alzheimer's disease (AD) have been validated and their evolution over time has been explored. In this study, multiple heterogeneous predictors of AD were combined using a supervised learning method called Disease State Index (DSI). The behavior of DSI values over time was examined to study disease progression quantitatively in a mild cognitive impairment (MCI) cohort. The DSI method was applied to longitudinal data from 140 MCI cases that progressed to AD and 149 MCI cases that did not progress to AD during the follow-up. The data included neuropsychological tests, brain volumes from magnetic resonance imaging, cerebrospinal fluid samples, and apolipoprotein E from the Alzheimer's Disease Neuroimaging Initiative database. Linear regression of the longitudinal DSI values (including the DSI value at the point of MCI to AD conversion) was performed for each subject having at least three DSI values available (147 non-converters, 126 converters). Converters had five times higher slopes and almost three times higher intercepts than non-converters. Two subgroups were found in the group of non-converters: one group with stable DSI values over time and another group with clearly increasing DSI values suggesting possible progression to AD in the future. The regression parameters differentiated between the converters and the non-converters with classification accuracy of 76.9{\%} for the slopes and 74.6{\%} for the intercepts. In conclusion, this study demonstrated that quantifying longitudinal patient data using the DSI method provides valid information for follow-up of disease progression and support for decision making.",
keywords = "Alzheimer's disease, biomarkers, data mining, decision support techniques, early diagnosis, mild cognitive impairment",
author = "Hilkka Runtti and Jussi Mattila and {van Gils}, Mark and Juha Koikkalainen and Hilkka Soininen and Jyrki L{\"o}tj{\"o}nen",
note = "Project code: Salwe 72578 (1.1 WP302)",
year = "2014",
doi = "10.3233/JAD-130359",
language = "English",
volume = "39",
pages = "49--61",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "1",

}

Quantitative Evaluation of Disease Progression in a Longitudinal Mild Cognitive Impairment Cohort. / Runtti, Hilkka (Corresponding Author); Mattila, Jussi; van Gils, Mark; Koikkalainen, Juha; Soininen, Hilkka; Lötjönen, Jyrki.

In: Journal of Alzheimer's Disease, Vol. 39, No. 1, 2014, p. 49-61.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Quantitative Evaluation of Disease Progression in a Longitudinal Mild Cognitive Impairment Cohort

AU - Runtti, Hilkka

AU - Mattila, Jussi

AU - van Gils, Mark

AU - Koikkalainen, Juha

AU - Soininen, Hilkka

AU - Lötjönen, Jyrki

N1 - Project code: Salwe 72578 (1.1 WP302)

PY - 2014

Y1 - 2014

N2 - Several neuropsychological tests and biomarkers of Alzheimer's disease (AD) have been validated and their evolution over time has been explored. In this study, multiple heterogeneous predictors of AD were combined using a supervised learning method called Disease State Index (DSI). The behavior of DSI values over time was examined to study disease progression quantitatively in a mild cognitive impairment (MCI) cohort. The DSI method was applied to longitudinal data from 140 MCI cases that progressed to AD and 149 MCI cases that did not progress to AD during the follow-up. The data included neuropsychological tests, brain volumes from magnetic resonance imaging, cerebrospinal fluid samples, and apolipoprotein E from the Alzheimer's Disease Neuroimaging Initiative database. Linear regression of the longitudinal DSI values (including the DSI value at the point of MCI to AD conversion) was performed for each subject having at least three DSI values available (147 non-converters, 126 converters). Converters had five times higher slopes and almost three times higher intercepts than non-converters. Two subgroups were found in the group of non-converters: one group with stable DSI values over time and another group with clearly increasing DSI values suggesting possible progression to AD in the future. The regression parameters differentiated between the converters and the non-converters with classification accuracy of 76.9% for the slopes and 74.6% for the intercepts. In conclusion, this study demonstrated that quantifying longitudinal patient data using the DSI method provides valid information for follow-up of disease progression and support for decision making.

AB - Several neuropsychological tests and biomarkers of Alzheimer's disease (AD) have been validated and their evolution over time has been explored. In this study, multiple heterogeneous predictors of AD were combined using a supervised learning method called Disease State Index (DSI). The behavior of DSI values over time was examined to study disease progression quantitatively in a mild cognitive impairment (MCI) cohort. The DSI method was applied to longitudinal data from 140 MCI cases that progressed to AD and 149 MCI cases that did not progress to AD during the follow-up. The data included neuropsychological tests, brain volumes from magnetic resonance imaging, cerebrospinal fluid samples, and apolipoprotein E from the Alzheimer's Disease Neuroimaging Initiative database. Linear regression of the longitudinal DSI values (including the DSI value at the point of MCI to AD conversion) was performed for each subject having at least three DSI values available (147 non-converters, 126 converters). Converters had five times higher slopes and almost three times higher intercepts than non-converters. Two subgroups were found in the group of non-converters: one group with stable DSI values over time and another group with clearly increasing DSI values suggesting possible progression to AD in the future. The regression parameters differentiated between the converters and the non-converters with classification accuracy of 76.9% for the slopes and 74.6% for the intercepts. In conclusion, this study demonstrated that quantifying longitudinal patient data using the DSI method provides valid information for follow-up of disease progression and support for decision making.

KW - Alzheimer's disease

KW - biomarkers

KW - data mining

KW - decision support techniques

KW - early diagnosis

KW - mild cognitive impairment

U2 - 10.3233/JAD-130359

DO - 10.3233/JAD-130359

M3 - Article

VL - 39

SP - 49

EP - 61

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 1

ER -